MK-5720
/ Merck (MSD)
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
March 27, 2024
A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)
(clinicaltrials.gov)
- P1 | N=17 | Completed | Sponsor: Merck Sharp & Dohme LLC | Recruiting ➔ Completed | N=64 ➔ 17 | Trial completion date: Sep 2024 ➔ Feb 2024 | Trial primary completion date: Sep 2024 ➔ Feb 2024
Enrollment change • Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Psychiatry • Schizophrenia
September 22, 2023
A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)
(clinicaltrials.gov)
- P1 | N=64 | Recruiting | Sponsor: Merck Sharp & Dohme LLC | Not yet recruiting ➔ Recruiting
Enrollment open • CNS Disorders • Psychiatry • Schizophrenia
July 20, 2023
A Study of MK-5720 in Participants With Schizophrenia (MK-5720-001)
(clinicaltrials.gov)
- P1 | N=64 | Not yet recruiting | Sponsor: Merck Sharp & Dohme LLC
New P1 trial • CNS Disorders • Psychiatry • Schizophrenia
1 to 3
Of
3
Go to page
1